Apogee Therapeutics
Logotype for Apogee Therapeutics Inc

Apogee Therapeutics (APGE) investor relations material

Apogee Therapeutics Q2 2026 earnings summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Apogee Therapeutics Inc
Q2 2026 earnings summary10 Aug, 2026

Executive summary

  • Entered into a $100M revenue participation agreement with Blackstone Life Sciences (BXLS) for APG777 (zumilokibart), with up to $700M in additional milestone-based tranches.

  • BXLS receives tiered revenue share payments on global net sales of zumilokibart, with rates escalating upon additional funding tranches.

  • Pending acquisition by AbbVie for $135.11 per share in cash, valuing equity at $10.9 billion, expected to close in Q3 2026.

  • Seller retains operational control and must use commercially reasonable efforts to develop, obtain approval, and commercialize APG777.

  • Agreement includes detailed diligence, reporting, and audit rights for BXLS, as well as provisions for change of control and buy-back options.

Significant events and developments

  • Initial $100M upfront payment received; further tranches ($100M, $200M, $250–$400M) contingent on clinical and regulatory milestones (Phase 3 enrollment, positive data, FDA approval).

  • Definitive agreement for AbbVie acquisition announced in June 2026.

  • Positive 16-week Phase 2 APEX Part B results for zumilokibart in moderate-to-severe atopic dermatitis, supporting advancement to Phase 3.

  • Revenue share rates: up to 3.4375% on first $5B in annual sales, with caps and adjustments for additional tranches and buy-back scenarios.

  • BXLS granted a backup security interest in APG777 product rights and related assets, released upon certain payments or change of control.

Capital allocation and financing

  • $1.3 billion strategic financing from Blackstone Life Sciences to support late-stage development and commercialization.

  • Seller may seek up to $500M in additional debt financing, subject to negotiation and customary terms.

  • Restrictions on additional liens, senior debt, and monetization of APG777 product rights prior to termination of BXLS security interest.

  • Cash position strengthened to support self-sustainability through commercialization.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Apogee Therapeutics earnings date

Logotype for Apogee Therapeutics Inc
Q3 202624 Nov, 2026
Apogee Therapeutics
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next Apogee Therapeutics earnings date

Logotype for Apogee Therapeutics Inc
Q3 202624 Nov, 2026

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

Apogee Therapeutics Inc. (APGE) is a biotechnology company engaged in the development of differentiated biologics for the treatment of various inflammatory and immunology (I&I) diseases, including atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and other conditions with high unmet medical needs. The company's approach is focused on creating best-in-class therapies that aim to improve upon the current standard of care for these conditions. The company is headquartered in San Francisco, California, and Waltham, Massachusetts, and its shares are listed on the Nasdaq.